FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1837563532> ?p ?o ?g. }

• W1837563532 endingPage "5499" @default.
• W1837563532 startingPage "5499" @default.
• W1837563532 abstract "Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease Shreesh Ojha,1,* Hayate Javed,2,* Sheikh Azimullah,1 Salema B Abul Khair,2 M Emdadul Haque2 1Department of Pharmacology and Therapeutics, 2Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE *These authors contributed equally to this work Abstract: Parkinson’s disease (PD) is a chronic, progressive, and the second most common form of neurodegenerative disorders. In order to explore novel agents for the treatment of PD, in the current study, we have evaluated the neuroprotective efficacy of ferulic acid (FA) using rotenone (ROT)-induced rat model of PD. ROT was administered 2.5 mg/kg body weight to male Wistar rats for 4 weeks to induce the PD. Since PD is progressive and chronic in nature, the paradigm for evaluating FA was based on chronic administration for 4 weeks at the dose of 50 mg/kg, 30 minutes prior to ROT administration. ROT administration caused significant reduction in endogenous antioxidants such as superoxide dismutase, catalase, and glutathione. ROT challenge-induced lipid peroxidation evidenced by increased malondialdehyde following perturbation of antioxidant defense. Apart from oxidative stress, ROT also activated proinflammatory cytokines and enhanced inflammatory mediators such as cyclooxygenase-2 and inducible nitric oxide synthase. The immunofluorescence analysis revealed a significant increase in the number of activated microglia and astrocytes accompanied by a significant loss of dopamine (DA) neurons in the substantia nigra pars compacta area upon ROT injection. However, treatment with FA rescued DA neurons in substantia nigra pars compacta area and nerve terminals in the striatum from the ROT insult. FA treatment also restored antioxidant enzymes, prevented depletion of glutathione, and inhibited lipid peroxidation. Following treatment with FA, the inflammatory mediators such as cyclooxygenase-2 and inducible nitric oxide synthase and proinflammatory cytokines were also reduced. Further, the results were supported by a remarkable reduction of Iba-1 and GFAP hyperactivity clearly suggests attenuation of microglial and astrocytic activation. Results of our study suggest that FA has promising neuroprotective effect against degenerative changes in PD, and the protective effects are mediated through its antioxidant and anti-inflammatory properties. Keywords: neurodegeneration, neurotoxicity, neuroinflammation, reactive oxygen species" @default.
• W1837563532 created "2016-06-24" @default.
• W1837563532 creator A5015791582 @default.
• W1837563532 creator A5024379963 @default.
• W1837563532 creator A5025401719 @default.
• W1837563532 creator A5052132089 @default.
• W1837563532 creator A5054485606 @default.
• W1837563532 date "2015-10-01" @default.
• W1837563532 modified "2023-10-16" @default.
• W1837563532 title "Neuroprotective potential of ferulic acid in the rotenone model of Parkinson&rsquo;s disease" @default.
• W1837563532 cites W1504584187 @default.
• W1837563532 cites W1522510037 @default.
• W1837563532 cites W1603237166 @default.
• W1837563532 cites W1963557538 @default.
• W1837563532 cites W1965854886 @default.
• W1837563532 cites W1966703352 @default.
• W1837563532 cites W1969280474 @default.
• W1837563532 cites W1975303582 @default.
• W1837563532 cites W1976325983 @default.
• W1837563532 cites W1978236377 @default.
• W1837563532 cites W1994054982 @default.
• W1837563532 cites W1995246942 @default.
• W1837563532 cites W1998791390 @default.
• W1837563532 cites W1999502797 @default.
• W1837563532 cites W2007258895 @default.
• W1837563532 cites W2011928235 @default.
• W1837563532 cites W2021899761 @default.
• W1837563532 cites W2022687465 @default.
• W1837563532 cites W2029503022 @default.
• W1837563532 cites W2031381001 @default.
• W1837563532 cites W2034459418 @default.
• W1837563532 cites W2036863248 @default.
• W1837563532 cites W2046391673 @default.
• W1837563532 cites W2050786534 @default.
• W1837563532 cites W2050865611 @default.
• W1837563532 cites W2052562226 @default.
• W1837563532 cites W2052967774 @default.
• W1837563532 cites W2076333673 @default.
• W1837563532 cites W2082240838 @default.
• W1837563532 cites W2087929778 @default.
• W1837563532 cites W2104476359 @default.
• W1837563532 cites W2112765817 @default.
• W1837563532 cites W2113192813 @default.
• W1837563532 cites W2129174837 @default.
• W1837563532 cites W2158601502 @default.
• W1837563532 cites W2163290644 @default.
• W1837563532 cites W2221360351 @default.
• W1837563532 doi "https://doi.org/10.2147/dddt.s90616" @default.
• W1837563532 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4603721" @default.
• W1837563532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26504373" @default.
• W1837563532 hasPublicationYear "2015" @default.
• W1837563532 type Work @default.
• W1837563532 sameAs 1837563532 @default.
• W1837563532 citedByCount "64" @default.
• W1837563532 countsByYear W18375635322016 @default.
• W1837563532 countsByYear W18375635322017 @default.
• W1837563532 countsByYear W18375635322018 @default.
• W1837563532 countsByYear W18375635322019 @default.
• W1837563532 countsByYear W18375635322020 @default.
• W1837563532 countsByYear W18375635322021 @default.
• W1837563532 countsByYear W18375635322022 @default.
• W1837563532 countsByYear W18375635322023 @default.
• W1837563532 crossrefType "journal-article" @default.
• W1837563532 hasAuthorship W1837563532A5015791582 @default.
• W1837563532 hasAuthorship W1837563532A5024379963 @default.
• W1837563532 hasAuthorship W1837563532A5025401719 @default.
• W1837563532 hasAuthorship W1837563532A5052132089 @default.
• W1837563532 hasAuthorship W1837563532A5054485606 @default.
• W1837563532 hasBestOaLocation W18375635321 @default.
• W1837563532 hasConcept C126322002 @default.
• W1837563532 hasConcept C185592680 @default.
• W1837563532 hasConcept C25498285 @default.
• W1837563532 hasConcept C2775838275 @default.
• W1837563532 hasConcept C2776151105 @default.
• W1837563532 hasConcept C2776773494 @default.
• W1837563532 hasConcept C2778389096 @default.
• W1837563532 hasConcept C2778401633 @default.
• W1837563532 hasConcept C2779134260 @default.
• W1837563532 hasConcept C2779734285 @default.
• W1837563532 hasConcept C2780213334 @default.
• W1837563532 hasConcept C2780829032 @default.
• W1837563532 hasConcept C2780938664 @default.
• W1837563532 hasConcept C28859421 @default.
• W1837563532 hasConcept C55493867 @default.
• W1837563532 hasConcept C71924100 @default.
• W1837563532 hasConcept C98274493 @default.
• W1837563532 hasConceptScore W1837563532C126322002 @default.
• W1837563532 hasConceptScore W1837563532C185592680 @default.
• W1837563532 hasConceptScore W1837563532C25498285 @default.
• W1837563532 hasConceptScore W1837563532C2775838275 @default.
• W1837563532 hasConceptScore W1837563532C2776151105 @default.
• W1837563532 hasConceptScore W1837563532C2776773494 @default.
• W1837563532 hasConceptScore W1837563532C2778389096 @default.
• W1837563532 hasConceptScore W1837563532C2778401633 @default.
• W1837563532 hasConceptScore W1837563532C2779134260 @default.
• W1837563532 hasConceptScore W1837563532C2779734285 @default.
• W1837563532 hasConceptScore W1837563532C2780213334 @default.
• W1837563532 hasConceptScore W1837563532C2780829032 @default.

• next